Trial | NCT01316393  Report issue

Title

Effects of Mucoprotective Product on Xerostomia
Clinical Evaluation of a Salivary Substitute and a Mucoprotective Product on Xerostomia in Head-and-neck Cancer Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    20
In the present study with a randomized, cross-over, blind, placebo controlled design, the effects of a salivary substitute product and a new mucoprotective product with similar mechanisms of action but with different composition and characteristics will be evaluated in cancer patients suffering from xerostomia.
Study Started
Feb 28
2011
Primary Completion
May 31
2011
Study Completion
Jun 30
2011
Last Update
Nov 09
2011
Estimate

Other XER2020

mucoprotective product

XER2020 Experimental

mucoprotective product

Saliva Natura Active Comparator

salivary substitute

XER2020 placebo Placebo Comparator

Criteria 

Inclusion Criteria:

The patient must be at least 18 years of age.
The patient must have clinical symptoms of xerostomia (dry mouth) due to treatment of head and neck cancer
The patient must understand and consent in writing to the procedure.

Exclusion Criteria:

Do not meet the criterion for "dry mouth" regarding saliva secretion threshold values.
Known allergy to ingredients in the products to be used in the trial and/or allergy to soy, peanuts, citrus fruit,Yerba Santa or methyl parabene
Patients who are unable or unwilling to cooperate with study procedures.
No Results Posted